Vaxcyte (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 10,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $53.00, for a total transaction of $530,000.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at $5,532,935. The trade was a 8.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $51.44 on Friday. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The firm has a 50-day moving average price of $53.56 and a two-hundred day moving average price of $52.70. The firm has a market cap of $7.43 billion, a price-to-earnings ratio of -7.48 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the firm posted ($1.04) earnings per share. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -7.56 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after acquiring an additional 3,188,687 shares during the period. Vanguard Group Inc. boosted its position in Vaxcyte by 2.7% during the third quarter. Vanguard Group Inc. now owns 12,320,453 shares of the company’s stock worth $443,783,000 after purchasing an additional 323,368 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in Vaxcyte by 35.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock worth $521,213,000 after purchasing an additional 2,981,038 shares during the period. Wellington Management Group LLP increased its stake in shares of Vaxcyte by 18.5% in the fourth quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock worth $275,286,000 after purchasing an additional 933,539 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Vaxcyte by 4.1% in the fourth quarter. State Street Corp now owns 4,980,005 shares of the company’s stock worth $229,777,000 after purchasing an additional 194,116 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. BTIG Research lifted their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.